FDG-PET predicted unfavorable tumor histology in living donor liver transplant recipients; a retrospective cohort study

Ling, Louis Leong-Liung; Hsu, Chien‐Chin; Yong, Chee‐Chien; Elsarawy, Ahmed M.; Chan, Yi‐Chia; Wang, Chih-Chi; Li, Weifeng; Lin, Tsan‐Shiun; Kuo, Fang-Ying; Cheng, Yu‐Fan; Lin, Li-Man; Chen, Chao‐Long; Lin, Chih‐Che

doi:10.1016/j.ijsu.2019.07.035

Cited by 11 publications

(39 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Whether liver transplantation could achieve a better outcome than resection remains unclear. Ling et al 13 performed living donor liver transplantation for three patients with early stage sarcomatoid HCC (single tumor <3 cm, normalα‐fetoprotein level, and without microvascular invasion). Out of the three patients, two developed tumor recurrence within 6 months after transplantation, the other one (tumor size 1.0 cm) did not suffer recurrence during a 12.3 months follow‐up.…”

Section: Discussionmentioning

confidence: 99%

Sarcomatoid hepatocellular carcinoma: From clinical features to cancer genome

Zhang

Feng

et al. 2021

Cancer Medicine

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Sarcomatoid hepatocellular carcinoma: From clinical features to cancer genome

Zhang

Feng

et al. 2021

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…Mycophenolate mofetil (CellCept; Roche, Humacoa, Puerto Rico) was continuously administered at 1 g/d. Patients with a diagnosis of unfavorable tumor histology or confirmed recurrences were given sirolimus (Rapamune; Pfizer, NY, USA) at a dose to maintain trough levels at 3–8 ng/mL ( Figure 1 ) [ 14 ].…”

Section: Methodsmentioning

confidence: 99%

Can Microscopic Biliary Reconstruction Reduce Biliary Complication Rate in ABO-Incompatible Adult Living Donor Liver Transplantation?

Lin

et al. 2021

Ann Transplant

Self Cite

View full text Add to dashboard Cite

Background With the introduction of rituximab, ABO-incompatible (ABOi) living donor liver transplantation (LDLT) has been considered a feasible and safe procedure to overcome the shortage of organ donors. However, higher biliary complication rates remain an unresolved problem in the ABOi group. In our center, biliary anastomosis has been done with microscopic biliary reconstruction (MBR), which effectively reduced the biliary complication rate. The aim of the current study was to investigate whether the microscopic approach reduced anastomotic biliary complications in ABOi LDLT. Material/Methods From March 2006 to December 2018, 30 adult ABOi and 60 ABO-compatible (ABOc) LDLT patients were selected from over 1300 recipients through 1: 2 propensity score-matched cohorts. All patients received MBR during the transplantation. Biliary complications included bile leakage and biliary stricture. Patients with diffuse intrahepatic biliary stricture were excluded from analysis. Results Patient characteristics were similar in the 2 groups. There was no in-hospital mortality in the ABOi LDLT. The long-term survival rates of the ABOi patients were comparable to those of the patients that underwent ABOc LDLT (87.1% vs 87.4%, P =0.964). Those in the ABOi group with anastomotic biliary complications were about 40%, which was higher than in the ABOc patients (40% vs 15%, P =0.01). Conclusions Microscopic biliary reconstruction does not help to reduce the high biliary complication rate in ABOi LDLT. Further investigation and identification regarding other risk factors and precautionary measures involving immunologic and adaptation mechanisms are needed.

show abstract

“…In recent years, a molecular imaging modality, 18 F-FDG PET/CT, has been widely applied to the diagnosis, staging, re-staging, and efficacy evaluation of tumors. Since the degree of glucose metabolism is closely related to the malignancy of the tumor, the predictive value of pre-transplantation 18 F-FDG PET/CT imaging for the recurrence of HCC after LT has been verified by several studies that have retrospectively analyzed the correlation between glucose metabolism and recurrence [5][6][7][8][9][10][11]. However, some HCC patients in these studies had already received other treatments, such as liver tumor transarterial chemoembolization (TACE), local radiofrequency ablation (RFA), and neoadjuvant chemotherapy, before LT. As these treatments inevitably affect the activity of the tumor, the level of tumor glucose metabolism is correspondingly inhibited, compromising its use in predicting HCC recurrence after LT.…”

Section: Introductionmentioning

confidence: 97%

Investigating the value of pre-treatment 18F-FDG PET/CT in predicting the pathological characteristic of hepatocellular carcinoma and recurrence after liver transplantation

Yin

Mao

et al. 2021

Abdom Radiol

View full text Add to dashboard Cite

The aim of this study is to investigate the value of pre-treatment 18 F-FDG PET/CT in predicting the pathological characteristic of HCC and recurrence after liver transplantation (LT). Methods A total of 34 patients who underwent 18 F-FDG PET/CT before LT for HCC and did not receive any other treatment were retrospectively enrolled in the study. The maximal standard uptake value of the tumor (T-SUVmax), normal liver tissues (L-SUVmax), and mediastinal blood pool (B-SUVmax) were derived, followed by the calculations of the T-SUVmax/L-SUVmax (T/L) and the T-SUVmax/B-SUVmax (T/B) ratios. Combined with the post-transplantation pathological results and ROC curve, the performance in predicting the pathological characteristic and the recurrence after LT were evaluated.

show abstract

FDG-PET predicted unfavorable tumor histology in living donor liver transplant recipients; a retrospective cohort study

Cited by 11 publications

References 46 publications

Sarcomatoid hepatocellular carcinoma: From clinical features to cancer genome

Sarcomatoid hepatocellular carcinoma: From clinical features to cancer genome

Can Microscopic Biliary Reconstruction Reduce Biliary Complication Rate in ABO-Incompatible Adult Living Donor Liver Transplantation?

Investigating the value of pre-treatment 18F-FDG PET/CT in predicting the pathological characteristic of hepatocellular carcinoma and recurrence after liver transplantation

Contact Info

Product

Resources

About